About Voyager Therapeutics
Voyager Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2014 by Steven M Paul. Gene Therapy to treat CNS diseases such as Parkinsons disease, ALS. Voyager Therapeutics has raised $105 million across 5 funding rounds from investors including Neurocrine, Brookside Capital and Wellington. The company has 172 employees. Its chief executive, as recorded, is Al Sandrock. Voyager Therapeutics offers products and services including VY7523 and TRACER Platform. Its focus areas include Life Sciences, Gene Therapy, DNA and dsDNA. Its legal entity is Voyager Therapeutics, Inc. Its competitors include Biogen, Denali Therapeutics and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The companys initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinsons disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreichs ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
- Headquarters Cambridge, United States
- Employees 172
- Founders Steven M Paul
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website voyagertherapeutics.com
- Social LinkedIn X
- Legal Name Voyager Therapeutics, Inc.
- Annual Revenue$40.37 M (USD)-49.53as on Dec 31, 2025
- Net Profit-$119.72 M (USD)-84.18as on Dec 31, 2025
- EBITDA-$127.78 M (USD)-62.67as on Dec 31, 2025
- Total Equity Funding$105M (USD)
in 5 rounds
- Latest Funding Round$20M (USD), Post-IPO
Jan 2024
- InvestorsNeurocrine
& 5 more
- Employee Count172
Products & Services of Voyager Therapeutics
Voyager Therapeutics offers a comprehensive portfolio of products and services, including VY7523 and TRACER Platform.
Therapy targeting Alzheimer's disease through genetic modification.
Platform for discovering AAV capsids to cross blood-brain barrier.
Funding Insights of Voyager Therapeutics
Voyager Therapeutics has successfully raised a total of $105M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $105M
- Total Rounds 5
- Last Round Post-IPO — $20M
- First Round $45M
(Feb 2014)
- Investors Count 6
All 5 funding rounds of Voyager Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $20M | Post-IPO | – | – | – |
| Mar 2023 | $39.03M | Post-IPO | – | – | – |
| Jan 2019 | $50M | Post-IPO | – | – | |
| Apr 2015 | $60M | Series B | – | Brookside Capital, PFM Health Sciences | |
| Feb 2014 | $45M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Voyager Therapeutics
Voyager Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Neurocrine, Brookside Capital and Wellington.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | neurocrine.com | San Diego, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States |
Investor details for Voyager Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Voyager Therapeutics
50 people are tracked at Voyager Therapeutics (29 in leadership, 5 in board & advisors, 16 in team); the tracked headcount is 172.
| Name | Role | Group |
|---|---|---|
Steven M Paul | Co-Founder | Leadership |
Al Sandrock | CEO | Leadership |
Amy LaPlante | Vice President, Human Resources | Leadership |
Mathieu Nonnenmacher | Vice President - Gene Therapy | Leadership |
Tejaswi Rampure | Vice President It, Lab Ops & Facilities | Leadership |
Scott Townsend | Senior Vice President Of Legal Affairs And Chief Corporate Counsel | Leadership |
Sarah Piantedosi | Director Clinical Operations | Leadership |
Eddie Arruda | Director of Facilities | Leadership |
Jacquelyn Fahey Sandell | Chief Legal Officer And Secretary | Leadership |
Amy Quinlan | VP Of Finance | Leadership |
Jay Hou | Vice President, Vector Engineering | Leadership |
Kumar Dhanasekharan | Svp, Head Of Technical Operations | Leadership |
Elena Ratti | Vice President Clinical Development | Leadership |
Trista Morrison | Chief of Staff & SVP, Corporate Affairs | Leadership |
Eric Hall | Vp, Corporate And Business Development | Leadership |
Todd Carter | Chief Scientific Officer | Leadership |
Robin Swartz | COO | Leadership |
Nathan Jorgensen | Chief Financial Officer | Leadership |
Tom E. | Associate Director, Downstream Process Development | Leadership |
Raj Rajagovindan | Vice President, Translational Medicine | Leadership |
30 more people are available in the full profile.
Complete people profiles for Voyager Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Voyager Therapeutics
Voyager Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VYGR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Nov 2015
- Listed onNASDAQ: VYGR
- Listed entityVoyager Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS92915B1061
- Share price$2.15 (-5.29% on the day) · 2026-10-13
- Market capitalisation$132.5M
- EPS (diluted, trailing year)$-1.81
- Volume (last session)1,060,673
Financials of Voyager Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $40.4M | -$119.7M | -$127.8M |
| 2024 | $80.0M | -$65.0M | -$78.6M |
| 2023 | $250.0M | $132.3M | $126.5M |
| 2022 | $40.9M | -$46.4M | -$44.6M |
| 2021 | $37.4M | -$71.2M | -$65.8M |
Detailed financial statements for Voyager Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Voyager Therapeutics
4 dated milestones of Voyager Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Voyager Therapeutics is founded.
- Funding First funding round of $45.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Competitors of Voyager Therapeutics
Voyager Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Voyager Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Voyager Therapeutics
The website of Voyager Therapeutics (voyagertherapeutics.com) receives about 8.8K visits a month and ranks #2,249,869 among all websites worldwide, #3,062 in Biotechnology and Pharmaceuticals.
- Monthly visits8.8K
▲ 7.1% vs previous month
- Unique visitors3.3K
per month
- Global rank#2,249,869
among all websites
- Category rank#3,062
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit2.7
- Average visit1 min 08 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Voyager Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| marinuspharma.com | 100% | 2.4K | #5,529,430 | View details | |
| sperotherapeutics.com | 99% | 2.3K | #4,462,927 | View details | |
ir.fatetherapeutics.com | ir.fatetherapeutics.com | 98% | – | ||
| contractpharma.com | 97% | 67.7K | #631,663 | View details | |
| biopharmadive.com | 97% | 680.7K | #208,628 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Voyager Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Voyager Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Voyager Therapeutics
Complete news archive for Voyager Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Voyager Therapeutics
Voyager Therapeutics was founded in 2014.
Voyager Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Al Sandrock is the CEO of Voyager Therapeutics, as recorded in our data.
Voyager Therapeutics is a funded company, having raised a total of $105M across 5 funding rounds to date. The company's 1st funding round was a Series A of $45M, raised on Feb 2014.
Voyager Therapeutics has 172 employees.
Annual revenue of Voyager Therapeutics is $40.37M as on Dec 31, 2025.
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The companys initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinsons disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreichs ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Voyager Therapeutics's top competitors include Spark Therapeutics, Denali Therapeutics and Biogen.
Voyager Therapeutics offers VY7523 and TRACER Platform.
Yes, Voyager Therapeutics is publicly traded on NASDAQ under the ticker symbol VYGR.
Voyager Therapeutics has 6 investors. Key investors include Neurocrine, Brookside Capital, Wellington, Casdin Capital, and PFM Health Sciences.
Voyager Therapeutics operates through Voyager Therapeutics, Inc..